Hively Brad's Form 4 filing
Starling Oncology, Inc. (DFPH) · filed Dec 2, 2024
- Accession no.
- 0001799191-24-000063
- Filed
- Dec 2, 2024, 4:04 PM ET
- Trade date
- Nov 12-Dec 2, 2024
- Filing delay
- 20 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $50.0K. It was filed 20 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hively BradCIK 0001891124 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Common stock | JOtherDisposed | −353,450 | $0.00 | $0 | 366,753 | Direct | |
| Nov 26, 2024 | Common stock | PPurchaseAcquired | +250,000 | $0.17 | +$42,500 | 616,753 | Direct | |
| Dec 2, 2024 | Common stock | PPurchaseAcquired | +50,000 | $0.15 | +$7,500 | 666,753 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.